Introduction: Previous studies have suggested that metformin use may enhance the therapeutic effect of progestin therapy for endometrial hyperplasia or malignancy. However, it is not known how the impact of concurrent metformin may be altered by route of progestin therapy, either locally via an intrauterine device or systemically. This study examined the effectiveness of concurrent metformin use and progestin therapy for women with complex atypical hyperplasia stratified by progestin route (systemic vs local).
View Article and Find Full Text PDFBackground: Though hysterectomy remains the standard treatment for complex atypical hyperplasia, patients who desire fertility or who are poor surgical candidates may opt for progestin therapy. However, the effectiveness of the levonorgestrel-releasing intrauterine device compared to systemic therapy in the treatment of complex atypical hyperplasia has not been well studied.
Objective: We sought to examine differences in treatment response between local progestin therapy with the levonorgestrel-releasing intrauterine device and systemic progestin therapy in women with complex atypical hyperplasia.
Objective: To examine survival of teenage women with pregnancies complicated by primary ovarian cancer.
Methods: This is a secondary analysis of a previously organized systematic literature review of primary ovarian cancer diagnosed during pregnancy. Cases eligible for analysis were patients whose age at cancer diagnosis and survival outcome were known (n=201).
•Experienced prolonged intubation after robotic hysterectomy for endometrial cancer•Risk triad: Trendelenburg position, high pneumo-pressure, and excess hydration•Recognition of the risk triad is key to avoiding airway complications in robotic surgery.•Introduction of a 5-step method to prevent airway complications in robotic surgery.
View Article and Find Full Text PDF